CITANEST 2% POLYAMP DUOFIT prilocaine hydrochloride 100mg/5mL injection BP ampoule

Quốc gia: Úc

Ngôn ngữ: Tiếng Anh

Nguồn: Department of Health (Therapeutic Goods Administration)

Thành phần hoạt chất:

prilocaine hydrochloride, Quantity: 20 mg/mL

Sẵn có từ:

Aspen Pharmacare Australia Pty Ltd

Dạng dược phẩm:

Injection, solution

Thành phần:

Excipient Ingredients: sodium hydroxide; sodium chloride; water for injections

Tuyến hành chính:

Epidural, Intramuscular, Intravenous, Peridural, Subcutaneous

Các đơn vị trong gói:

10 x 5mL

Loại thuốc theo toa:

(S4) Prescription Only Medicine

Chỉ dẫn điều trị:

CITANEST Solutions are indicated for the production of local or regional anaesthesia by infiltration techniques; intravenous regional anesthesia; by peripheral nerve block techniques such as intercostal blocks; major plexus blocks such as brachial plexus blocks and by epidural and subarachnoid blocks.

Tóm tắt sản phẩm:

Visual Identification: A clear colourless, particle free solution.; Container Type: Ampoule; Container Material: PE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Tình trạng ủy quyền:

Licence status A

Ngày ủy quyền:

1996-05-02

Đặc tính sản phẩm

1
AUSTRALIAN PRODUCT INFORMATION
CITANEST
®
(PRILOCAINE HYDROCHLORIDE)
INJECTION SOLUTIONS FOR THE PRODUCTION OF LOCAL OR REGIONAL
ANAESTHESIA
1
NAME OF THE MEDICINE
Prilocaine hydrochloride
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
The active ingredient in CITANEST is prilocaine hydrochloride.
CITANEST solution for injection contains the following inactive
ingredients: sodium chloride,
water for injection, hydrochloric acid and/or sodium hydroxide for pH
adjustment.
3
PHARMACEUTICAL FORM
All CITANEST solutions are clear and colourless.
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
CITANEST
solutions
are
indicated
for
the
production
of
local
or
regional
anaesthesia
by
infiltration techniques; intravenous regional anaesthesia; by
peripheral nerve block techniques
such as intercostal blocks; major plexus blocks such as brachial
plexus blocks and by epidural and
subarachnoid blocks.
4.2
D
OSE AND METHOD OF ADMINISTRATION
The lowest dosage that results in effective anaesthesia should be used
and should be based on the
status of the patient and the type of regional anaesthesia intended.
The product contains no antimicrobial preservative. An ampoule or
single dose vial should be
used on one patient on one occasion only. Solutions showing
discolouration and unused portions
of solutions from single dose vials and ampoules should be discarded.
ADULTS
Table 1. Recommended dosages for CITANEST plain solutions for various
anaesthetic procedures
in the average, healthy, 70 kg adult patient.
PROCEDURE
CONCENTRATION
%
VOLUME ML
PLAIN
INFILTRATION
0.5
80
1.0
40
2.0
20
INTRAVENOUS REGIONAL
Upper Extremities
0.5
40 - 60
Lower Extremities
0.5
60 - 80
PLEXUS NERVE BLOCKS
2
Brachial
2.0
20
PERIPHERAL NERVE BLOCKS
Intercostal
1.0
-
Paravertebral
1.0
3 - 5
Sciatic femoral
2.0
20
PROCEDURE
CONCENTRATION
%
VOLUME ML
PLAIN
EPIDURAL*
THORACIC
1.0
10 - 20
Analgesia
1.0
30
Anaesthesia
2.0
20
CAUDAL
Analgesia
1.0
30
Anaesthesia
2.0
20
* Dose determined by number of segments to be anaesthetised (2-3
mL/segment)
NOTE:
1.
RECOMMENDED DOS